![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: IRF2BP1 |
Gene summary for IRF2BP1 |
![]() |
Gene information | Species | Human | Gene symbol | IRF2BP1 | Gene ID | 26145 |
Gene name | interferon regulatory factor 2 binding protein 1 | |
Gene Alias | IRF2BP1 | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q8IU81 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26145 | IRF2BP1 | HCC1_Meng | Human | Liver | HCC | 1.03e-30 | 2.49e-02 | 0.0246 |
26145 | IRF2BP1 | HCC2_Meng | Human | Liver | HCC | 4.26e-14 | 3.09e-02 | 0.0107 |
26145 | IRF2BP1 | Pt13.b | Human | Liver | HCC | 1.72e-03 | 3.02e-02 | 0.0251 |
26145 | IRF2BP1 | S014 | Human | Liver | HCC | 7.87e-20 | 5.85e-01 | 0.2254 |
26145 | IRF2BP1 | S015 | Human | Liver | HCC | 8.77e-19 | 6.20e-01 | 0.2375 |
26145 | IRF2BP1 | S016 | Human | Liver | HCC | 5.73e-23 | 6.39e-01 | 0.2243 |
26145 | IRF2BP1 | S027 | Human | Liver | HCC | 4.17e-07 | 3.50e-01 | 0.2446 |
26145 | IRF2BP1 | S028 | Human | Liver | HCC | 3.02e-12 | 3.89e-01 | 0.2503 |
26145 | IRF2BP1 | S029 | Human | Liver | HCC | 2.18e-13 | 4.31e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000020921 | Liver | HCC | protein polyubiquitination | 151/7958 | 236/18723 | 1.90e-11 | 7.59e-10 | 151 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRF2BP1 | SNV | Missense_Mutation | c.778N>A | p.Asp260Asn | p.D260N | Q8IU81 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
IRF2BP1 | SNV | Missense_Mutation | novel | c.647N>A | p.Arg216Gln | p.R216Q | Q8IU81 | protein_coding | deleterious(0.02) | possibly_damaging(0.886) | TCGA-GM-A2DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
IRF2BP1 | SNV | Missense_Mutation | novel | c.439G>A | p.Ala147Thr | p.A147T | Q8IU81 | protein_coding | tolerated(0.15) | benign(0.041) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRF2BP1 | SNV | Missense_Mutation | c.65N>C | p.Trp22Ser | p.W22S | Q8IU81 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-FU-A23K-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
IRF2BP1 | SNV | Missense_Mutation | c.974G>A | p.Gly325Glu | p.G325E | Q8IU81 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
IRF2BP1 | SNV | Missense_Mutation | novel | c.524N>A | p.Gly175Glu | p.G175E | Q8IU81 | protein_coding | tolerated(0.3) | possibly_damaging(0.888) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
IRF2BP1 | SNV | Missense_Mutation | novel | c.674G>A | p.Arg225His | p.R225H | Q8IU81 | protein_coding | tolerated(0.07) | benign(0.049) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
IRF2BP1 | SNV | Missense_Mutation | c.1610N>T | p.Ala537Val | p.A537V | Q8IU81 | protein_coding | deleterious(0.01) | benign(0.147) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IRF2BP1 | SNV | Missense_Mutation | novel | c.1745G>A | p.Arg582Gln | p.R582Q | Q8IU81 | protein_coding | deleterious(0.01) | possibly_damaging(0.665) | TCGA-A5-A7WJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IRF2BP1 | SNV | Missense_Mutation | novel | c.491N>A | p.Pro164His | p.P164H | Q8IU81 | protein_coding | tolerated(0.22) | benign(0.012) | TCGA-AJ-A2QO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |